Cotinga Pharmaceuticals Net debt/EBITDA
¿Qué es el Net debt/EBITDA de Cotinga Pharmaceuticals?
El Net debt/EBITDA de Cotinga Pharmaceuticals, Inc. es -0.40
¿Cuál es la definición de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA de compañías en Sector Health Care en TSXV en comparadas con Cotinga Pharmaceuticals
¿Qué hace Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Empresas con net debt/ebitda similar a Cotinga Pharmaceuticals
- PIMCO Strategic Income Fund Inc tiene Net debt/EBITDA de -0.41
- Euro Sun Mining tiene Net debt/EBITDA de -0.41
- Biomarin Pharmaceutical tiene Net debt/EBITDA de -0.40
- Innovative Designs tiene Net debt/EBITDA de -0.40
- ProntoForms tiene Net debt/EBITDA de -0.40
- RiceBran Technologies tiene Net debt/EBITDA de -0.40
- Cotinga Pharmaceuticals tiene Net debt/EBITDA de -0.40
- Ansys tiene Net debt/EBITDA de -0.40
- Daimler AG tiene Net debt/EBITDA de -0.40
- Mercedes-Benz AG tiene Net debt/EBITDA de -0.40
- ASICS tiene Net debt/EBITDA de -0.40
- Strattec Security tiene Net debt/EBITDA de -0.40
- vTv Therapeutics Inc tiene Net debt/EBITDA de -0.39